e.g. mhealth
Search Results (1 to 9 of 9 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 2 JMIR Research Protocols
- 2 Journal of Medical Internet Research
- 1 Interactive Journal of Medical Research
- 1 JMIR Cardio
- 1 JMIR Formative Research
- 1 JMIR Public Health and Surveillance
- 1 JMIR mHealth and uHealth
- 0 Medicine 2.0
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
The FLI is a biomarker for noninvasive fat layer prediction of nonalcoholic fatty liver disease (NAFLD). It has been validated against imaging methods for fatty liver diagnosis in the United States, with an accuracy of 0.84 (95% CI 0.81-0.87) [14]. Also, the FLI was validated with an area under the curve value of 0.87 or 0.785 in the Korean population [20,21].
JMIR Public Health Surveill 2024;10:e57168
Download Citation: END BibTex RIS
We read with great interest the article by Kwon et al [1] in the Journal of Medical Internet Research that described an app for lifestyle coaching intervention for patients with nonalcoholic fatty liver disease (NAFLD). With the paradigm shift in medicine, we are delighted to find that the study took into account the importance of psychological and social factors for patients. Digital therapeutics have shown remarkable contributions in various fields [2].
J Med Internet Res 2024;26:e59208
Download Citation: END BibTex RIS
Nonalcoholic fatty liver disease (NAFLD) stands as the foremost chronic liver condition, impacting approximately 1.7 billion individuals worldwide. NAFLD manifests as a multifaceted chronic liver disorder marked by an excessive buildup of fat within liver tissue. As hepatic steatosis advances, it exacerbates the onset and progression of hepatitis and fibrosis, while heightening the likelihood of liver cancer.
JMIR Form Res 2024;8:e53654
Download Citation: END BibTex RIS
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world [1]. NAFLD is defined as >5% fat in the liver (steatosis) among people who drink moderate amounts or no alcohol and have no other chronic liver diseases [2]. NAFLD reflects a spectrum of liver pathologies, ranging from simple steatosis to a more severe condition called nonalcoholic steatohepatitis (NASH), which includes inflammation and potential scarring of the liver [3].
JMIR Cardio 2024;8:e52576
Download Citation: END BibTex RIS
NAFLD encompasses a spectrum of diseases including NAFL, which has a more benign course, and NASH, which can progress to cirrhosis and hepatocellular carcinoma (HCC) [6]. Due to the heterogeneous nature of the disease, the undetermined symptoms, and the high disease burden, there is increasing appreciation that NAFLD may also be becoming an important cause of HCC [7]. The reported global prevalence of NAFLD and HCC varies between 2% and 58.5% [8].
Interact J Med Res 2023;12:e40653
Download Citation: END BibTex RIS
Thus, to investigate the utility and cost-benefit of adding mp MRI into the care pathway of those with suspected NAFLD in Europe (European Union territories and United Kingdom [UK]), this randomized, multi-center, phase 4 control trial to investigate the use of mp MRI as a standardized diagnostic test for NAFLD/NASH was designed.
JMIR Res Protoc 2020;9(10):e19189
Download Citation: END BibTex RIS
This was part of the routine clinical service offered to overweight or obese NAFLD patients seen at the NAFLD clinic.
All outcomes were part of routine measurements taken by trained nurses and blood tests conducted at the outpatient NAFLD clinic. Assessors were not blinded to the groups allocated to the study participants. Body weight was measured using a calibrated digital weighing machine (Seca 767, Germany) to the nearest 0.1 kg.
JMIR Mhealth Uhealth 2020;8(4):e14802
Download Citation: END BibTex RIS
Obesity-associated diseases, such as type 2 diabetes mellitus (T2 DM) and nonalcoholic fatty liver disease (NAFLD), are major public health issues worldwide, affecting more than 6% and 25% of the world population, respectively [1,2]. The influence of gut bacteria on the development of obesity and metabolic syndrome is not entirely understood.
Numerous experimental studies show that gut bacteria are influential in the development of obesity.
JMIR Res Protoc 2019;8(6):e11553
Download Citation: END BibTex RIS
In the last few years, nonalcoholic fatty liver disease (NAFLD) has gained attention, owing to its highest increase in the incidence among chronic liver diseases worldwide [3,4,7-9]. Some researchers consider NAFLD as a hepatic manifestation of metabolic syndrome, whereas others consider it a consequence of metabolic syndrome [3,10-13].
J Med Internet Res 2019;21(1):e11250
Download Citation: END BibTex RIS